Hypermarcas (OTCMKTS:HYPMY) Reaches New 1-Year High – Still a Buy?

Hypermarcas (OTCMKTS:HYPMY)’s share price reached a new 52-week high on Tuesday . The company traded as high as $5.18 and last traded at $5.18, with a volume of 1176 shares traded. The stock had previously closed at $4.8750.

Hypermarcas Trading Down 1.4%

The company’s 50 day simple moving average is $4.45 and its 200-day simple moving average is $4.52. The firm has a market cap of $3.08 billion, a P/E ratio of 21.13 and a beta of 0.73. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.63.

Hypermarcas (OTCMKTS:HYPMY) last released its earnings results on Wednesday, November 12th. The company reported $0.13 EPS for the quarter. Hypermarcas had a return on equity of 6.99% and a net margin of 12.03%.The firm had revenue of $408.83 million for the quarter.

Hypermarcas Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.